# Inhibikase Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:53547177-59fc-48ea-9605-a3e44c358510 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/inhibikase-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 26 | | Claims under review | 1 | | Evidence records | 6 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-16T13:52:50.363049+00:00 | | Last reviewed | 2026-10-16T13:52:50.363049+00:00 | ## Identity - Legal name: Inhibikase Therapeutics, Inc. - Display name: Inhibikase Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-16T15:09:23.754842+00:00 | | Completeness | 0.409 | | Record Quality | 0.836 | | Directors | 10 | | Committees | 5 | | Governance events | 16 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Amit Munshi: Director. Status: current. Independent: true. Since: 2024-01-01. Committees: Compensation (member). claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:5 - Arvind Kush: Director. Status: current. Independent: true. Since: 2024-01-01. Committees: Audit (chair); Audit · Chair; Compensation (member); Compensation (member). claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6 - David Canner, Ph.D.: Director. Status: current. Independent: true. Since: 2024-01-01. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:8 - Mark Iwicki: Director. Status: current. Independent: false. Since: 2025-01-01. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:10 - Roberto Bellini: Director. Status: current. Independent: true. Since: 2024-01-01. Committees: Nominating and Governance (chair); Nominating and Governance · Chair (member). claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11 - Roy Freeman, M.D.: Director. Status: current. Independent: true. Since: 2020-01-01. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:12 - Vincent Aurentz: Director. Status: current. Independent: true. Since: 2025-01-01. Committees: Nominating and Governance (member). claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:13 - Chris Cabell, M.D.: Director. Status: unknown. Independent: false. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:7 - David McIntyre: Director. Status: unknown. Independent: false. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:9 - Dr. David Berman: Director (committee appointment). Status: unknown. Independent: NOT_PUBLISHED. Since: NOT_PUBLISHED. Committees: Audit (member); Compensation (chair). claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:17 ## Committees - Audit (audit). Chair: Arvind Kush. Members: Arvind Kush (chair, current); Dr. David Berman (member, current). committee_id=alpha:committee:inhibikase-therapeutics-inc:audit - Audit · Chair; Compensation (audit). Chair: NOT_PUBLISHED. Members: Arvind Kush (member, current). committee_id=alpha:committee:inhibikase-therapeutics-inc:audit-chair-compensation - Compensation (compensation). Chair: Dr. David Berman. Members: Dr. David Berman (chair, current); Amit Munshi (member, current); Arvind Kush (member, current). committee_id=alpha:committee:inhibikase-therapeutics-inc:compensation - Nominating and Governance (nominating_governance). Chair: Roberto Bellini. Members: Roberto Bellini (chair, current); Vincent Aurentz (member, current). committee_id=alpha:committee:inhibikase-therapeutics-inc:nominating-and-governance - Nominating and Governance · Chair (nominating_governance). Chair: NOT_PUBLISHED. Members: Roberto Bellini (member, current). committee_id=alpha:committee:inhibikase-therapeutics-inc:nominating-and-governance-chair ## Executive leadership - Chris Cabell, M.D.: President and Head of Research and Development [PRESIDENT]. Status: current. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:14 - David McIntyre: Chief Financial Officer [CFO]. Status: current. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:15 - Mark Iwicki: Chief Executive Officer and Director [CEO]. Status: current. claim_id=alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:16 ## Governance events - EXECUTIVE_APPOINTED: Chris Cabell, M.D. executive of Inhibikase Therapeutics, Inc., effective 2026-03-26. Effective: 2026-03-26. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:w44ar3ftq8vd - CFO_CHANGED: David McIntyre executive of Inhibikase Therapeutics, Inc., effective 2026-03-26. Effective: 2026-03-26. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1m9zk9b14qfty5 - CEO_CHANGED: Mark Iwicki executive of Inhibikase Therapeutics, Inc., effective 2026-03-26. Effective: 2026-03-26. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:xmfw6c19qw3nq - DIRECTOR_APPOINTED: Mark Iwicki seat on Inhibikase Therapeutics, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1gxqxaw1cwrr8e - DIRECTOR_APPOINTED: Vincent Aurentz seat on Inhibikase Therapeutics, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:xu5yvn1rftizp - COMMITTEE_MEMBER_ADDED: Vincent Aurentz member of Nominating and Governance, effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:5bc14klg7xcq - DIRECTOR_APPOINTED: Amit Munshi seat on Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:zoxstl14w5q3v - DIRECTOR_APPOINTED: Arvind Kush seat on Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:cvzup41ri85ws - DIRECTOR_APPOINTED: David Canner, Ph.D. seat on Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1tc35xefu9dqa - DIRECTOR_APPOINTED: Roberto Bellini seat on Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1i4q4h218pvifm - COMMITTEE_CREATED: Audit · Chair; Compensation committee of Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1q9ixsidcaasg - COMMITTEE_MEMBER_ADDED: Arvind Kush member of Audit · Chair; Compensation, effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:d7dmyqk3iah6 - COMMITTEE_MEMBER_ADDED: Amit Munshi member of Compensation, effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1jje2v8i9fy3w - COMMITTEE_CREATED: Nominating and Governance · Chair committee of Inhibikase Therapeutics, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:1f1thr8e53txq - COMMITTEE_MEMBER_ADDED: Roberto Bellini member of Nominating and Governance · Chair, effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:17cd0151grud3j - DIRECTOR_APPOINTED: Roy Freeman, M.D. seat on Inhibikase Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-16T13:52:50.363049+00:00. event_id=alpha:event:transition:5bk2hd1tmzbhp ## Scoped resources - `alpha://company/inhibikase-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record - `alpha://company/inhibikase-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=identity - `alpha://company/inhibikase-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/inhibikase-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=board - `alpha://company/inhibikase-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=committees - `alpha://company/inhibikase-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=leadership - `alpha://company/inhibikase-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=ownership - `alpha://company/inhibikase-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=financials - `alpha://company/inhibikase-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/inhibikase-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=compensation - `alpha://company/inhibikase-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=governance - `alpha://company/inhibikase-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/inhibikase-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=audit - `alpha://company/inhibikase-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=legal - `alpha://company/inhibikase-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=risk - `alpha://company/inhibikase-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=cyber - `alpha://company/inhibikase-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/inhibikase-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=agents - `alpha://company/inhibikase-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/inhibikase-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=events - `alpha://company/inhibikase-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=relationships - `alpha://company/inhibikase-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=assessments - `alpha://company/inhibikase-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:18: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:arvind-kush","name":"Arvind Kush"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:19: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:dennis-berman","name":"Dr. David Berman"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:21: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"chair","person":{"alpha_id":"alpha:person:dennis-berman","name":"Dr. David Berman"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:22: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:amit-munshi","name":"Amit Munshi"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:23: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:arvind-kush","name":"Arvind Kush"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:25: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"chair","person":{"alpha_id":"alpha:person:roberto-bellini","name":"Roberto Bellini"},"source_id":"board_seats"}` - Claim alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:26: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"member","person":{"alpha_id":"alpha:person:vincent-aurentz","name":"Vincent Aurentz"},"source_id":"board_seats"}` ## Leadership - Amit Munshi: Director, Compensation. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:5. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Arvind Kush: Director, Audit · Chair; Compensation. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Chris Cabell, M.D.: Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - David Canner, Ph.D.: Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:8. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - David McIntyre: Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:9. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Mark Iwicki: Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:10. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Roberto Bellini: Director, Nominating and Governance · Chair. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Roy Freeman, M.D.: Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:12. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Vincent Aurentz: Director, Nominating and Governance. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:13. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3. - Chris Cabell, M.D.: President and Head of Research and Development. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:14. Valid from: 2026-03-26. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:4677cf46d4312514a369c9980988ca1b826ef2c79f258338999aeefa62c8ce3f. - David McIntyre: Chief Financial Officer. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:15. Valid from: 2026-03-26. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:267fc6e9478bfc77e8e15176a516a660226d070498ea965a58148cae2381f6c9. - Mark Iwicki: Chief Executive Officer and Director. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:16. Valid from: 2026-03-26. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cee5c39c7287118d2ff6c66487225b929867ec0e421959c8e49a65ce773c4dff. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair Arvind Kush; Members Arvind Kush (Chair); Dr. David Berman. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Compensation: Chair Dr. David Berman; Members Dr. David Berman (Chair); Amit Munshi; Arvind Kush. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Nominating and Governance: Chair Roberto Bellini; Members Roberto Bellini (Chair); Vincent Aurentz. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:24. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Inhibikase Therapeutics, Inc.. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:44acc36f120ba32db38fd0069a50c407d44c5b165a1bdab4d97174b63aedf893. ## Entity Status - Public listing published. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:44acc36f120ba32db38fd0069a50c407d44c5b165a1bdab4d97174b63aedf893. ## Published Fact - US. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:44acc36f120ba32db38fd0069a50c407d44c5b165a1bdab4d97174b63aedf893. ## Committee Appointment - Arvind Kush: chair, Audit. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Dr. David Berman: member, Audit. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Dr. David Berman: chair, Compensation. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Amit Munshi: member, Compensation. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Arvind Kush: member, Compensation. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:23. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Roberto Bellini: chair, Nominating and Governance. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:25. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. - Vincent Aurentz: member, Nominating and Governance. Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_appointment:26. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949. ## Security Listing - IKT (NASDAQ). Claim: alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:security_listing:27. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:44acc36f120ba32db38fd0069a50c407d44c5b165a1bdab4d97174b63aedf893. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:44acc36f120ba32db38fd0069a50c407d44c5b165a1bdab4d97174b63aedf893: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/inhibikase-therapeutics-inc). - alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3: [Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12](https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm). - alpha:projection-evidence:document:4677cf46d4312514a369c9980988ca1b826ef2c79f258338999aeefa62c8ce3f: [IKT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm). - alpha:projection-evidence:document:267fc6e9478bfc77e8e15176a516a660226d070498ea965a58148cae2381f6c9: [IKT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm). - alpha:projection-evidence:document:cee5c39c7287118d2ff6c66487225b929867ec0e421959c8e49a65ce773c4dff: [IKT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm). - alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949: [Audit](https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/inhibikase-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/inhibikase-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/inhibikase-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-16T15:09:23.412532+00:00; recorded 2026-10-16T15:09:23.412532+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.